	US 12,240,907 B2
	N-terminal scFv multispecific binding molecules
Yang Shen, Scarsdale, NY (US); Ann-Hwee Lee, Ardsley, NY (US); Yan Yang, Mamaroneck, NY (US); and Chia-Yang Lin, Scarsdale, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Nov. 4, 2020, as Appl. No. 17/088,918.
Claims priority of provisional application 62/930,916, filed on Nov. 5, 2019.
Prior Publication US 2021/0130477 A1, May 6, 2021
Int. Cl. C07K 16/28 (2006.01); C07K 16/40 (2006.01)

CPC C07K 16/2863 (2013.01) [C07K 16/2896 (2013.01); C07K 16/40 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/52 (2013.01); C07K 2317/522 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01)]

18 Claims

1. A method, comprising contacting a cell expressing fibroblast growth factor receptor 3 (FGFR3) and amyloid precursor-like protein 2 (APLP2) with a multispecific binding molecule (MBM) comprising:

(a) a first polypeptide chain comprising, in an N- to C-terminal orientation, (i) an scFv comprising means for binding human APLP2, (ii) a first heavy chain region of a first Fab comprising means for binding human FGFR3, and (iii) a first Fc domain;

(b) a second polypeptide chain comprising, in an N- to C-terminal orientation, (i) a second heavy chain region of a second Fab comprising means for binding human FGFR3 and (ii) a second Fc domain;

(c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form the first Fab; and

(d) a fourth polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form the second Fab.